Darapladib

Darapladib

CAT N°: 16429
Price:

From 74.00 62.90

Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet activating factor acetylhydrolase (PAF-AH) or phospholipase A2 group 7 (PLA2G7), hydrolyzes glycerophospholipids to produce lyso-PAF/lyso-phosphatidylcholine and short and/or oxidized fatty acids, many of which have pro-inflammatory or pro-oxidative activities.{26682,26483} Darapladib is a reversible inhibitor of Lp-PLA2 (IC50 = 0.25 nM).{27391} It produces sustained inhibition of plasma Lp-PLA2 activity in humans receiving intensive atorvastatin therapy.{27387} Lp-PLA2 inhibition with darapladib also reduces the development of coronary atherosclerotic plaques.{27388,27390}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • N-[2-(diethylamino)ethyl]-2-[[(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-N-[[4′-(trifluoromethyl)[1,1′-biphenyl]-4-yl]methyl]-1H-cyclopentapyrimidine-1-acetamide
  • Correlated keywords
    • biochemical phospholipase inhibit atherosclerosis vascular disease inflammation oxidative injury SB480848 SB 435445 SB435445 reversible inhibitor Lp-PLA2 LpPLA2 plasma activity humans atorvastatin therapy coronary atherosclerotic plaque reduce reduction
  • Product Overview:
    Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet activating factor acetylhydrolase (PAF-AH) or phospholipase A2 group 7 (PLA2G7), hydrolyzes glycerophospholipids to produce lyso-PAF/lyso-phosphatidylcholine and short and/or oxidized fatty acids, many of which have pro-inflammatory or pro-oxidative activities.{26682,26483} Darapladib is a reversible inhibitor of Lp-PLA2 (IC50 = 0.25 nM).{27391} It produces sustained inhibition of plasma Lp-PLA2 activity in humans receiving intensive atorvastatin therapy.{27387} Lp-PLA2 inhibition with darapladib also reduces the development of coronary atherosclerotic plaques.{27388,27390}

We also advise you